LCMT2抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human placenta tissue lysate, Primary antibody: P07967(LTF Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07967(LTF Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

The LCMT2 (Leucine Carboxyl Methyltransferase 2) antibody is a tool used to study the enzyme LCMT2. a member of the methyltransferase family that plays a critical role in post-translational protein modification. LCMT2 catalyzes the methylation of the C-terminal leucine residue of the protein phosphatase 2A (PP2A) catalytic subunit, a key step in regulating PP2A assembly and activity. PP2A is a major serine/threonine phosphatase involved in diverse cellular processes, including cell cycle progression, signal transduction, and apoptosis. Methylation by LCMT2 promotes the formation of specific PP2A holoenzymes, which determine substrate specificity and functional diversity.

The LCMT2 antibody is widely used in research to detect endogenous LCMT2 expression, assess its interaction with PP2A subunits, and investigate its role in cellular pathways. It has applications in Western blotting, immunofluorescence, and immunoprecipitation. Studies involving this antibody often focus on diseases linked to PP2A dysregulation, such as cancer, neurodegenerative disorders, and cardiovascular conditions. For instance, altered LCMT2 expression has been implicated in tumorigenesis due to its impact on PP2A-dependent signaling networks.

Researchers also utilize the LCMT2 antibody to explore methylation-dependent mechanisms in cellular stress responses and metabolic regulation. Its specificity and reliability make it essential for elucidating LCMT2’s contribution to epigenetic and post-translational regulatory landscapes.